Challenges in Advanced Therapy Medicinal Product Development: A Survey Among Companies in Europe

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2018 Nov 21

PMID 30456217

Citations 33

Authors

Renske M T Ten Ham

Jarno Hoekman

Anke M Hovels

Andre W Broekmans

Hubert G M Leufkens

Olaf H Klungel

Affiliations

Soon will be listed here.

Abstract

Advanced therapy medicinal products (ATMPs) hold promise as treatments for previously untreatable and high-burden diseases. Expectations are high and active company pipelines are observed, yet only 10 market authorizations were approved in Europe. Our aim was to identify challenges experienced in European ATMP clinical development by companies. A survey-based cohort study was conducted among commercial ATMP developers. Respondents shared challenges experienced during various development phases, as well as developer and product characteristics. Descriptions of challenges were grouped in domains (clinical, financial, human resource management, regulatory, scientific, technical, other) and further categorized using thematic content analysis. A descriptive analysis was performed. We invited 271 commercial ATMP developers, of which 68 responded providing 243 challenges. Of products in development, 72% were in early clinical development and 40% were gene therapies. Most developers were small- or medium-sized enterprises (65%). The most often mentioned challenges were related to country-specific requirements (16%), manufacturing (15%), and clinical trial design (8%). The European ATMP field is still in its early stages, and developers experience challenges on many levels. Challenges are multifactorial and a mix of ATMP-specific and generic development aspects, such as new and orphan indications, novel technologies, and inexperience, adding complexity to development efforts.

Citing Articles

The Role and Challenges of Investigator-Initiated Trials in the Cell and Gene Therapy Products Boom in Mainland China.

Yang Y, Bian L, Cheng Y, Xu Y, Shao H, Rao J Clin Transl Sci. 2025; 18(2):e70148.

PMID: 39936621 PMC: 11815567. DOI: 10.1111/cts.70148.

Mesenchymal stromal cell therapies for traumatic neurological injuries.

Wang X, Wang Q, Xia Z, Yang Y, Dai X, Zhang C J Transl Med. 2024; 22(1):1055.

PMID: 39578845 PMC: 11583761. DOI: 10.1186/s12967-024-05725-3.

Bioengineering breakthroughs: The impact of stem cell models on advanced therapy medicinal product development.

Granjeiro J, Borchio P, Ribeiro I, Paiva K World J Stem Cells. 2024; 16(10):860-872.

PMID: 39493828 PMC: 11525646. DOI: 10.4252/wjsc.v16.i10.860.

Developing Advanced Chimeric Cell Therapy for Duchenne Muscular Dystrophy.

Budzynska K, Bozyk K, Jarosinska K, Ziemiecka A, Siemionow K, Siemionow M Int J Mol Sci. 2024; 25(20).

PMID: 39456730 PMC: 11507628. DOI: 10.3390/ijms252010947.

Synthesizing regulatory guidance for demonstrating preclinical efficacy and translating promising cell therapies to early phase clinical trials: a scoping review.

Jeffers M, Xi C, Bapuji R, Wotherspoon H, Kimmelman J, Bedford P BMC Med. 2024; 22(1):487.

PMID: 39443960 PMC: 11515533. DOI: 10.1186/s12916-024-03690-8.

References

Pignatti F, Aronsson B, Gate N, Vamvakas S, Wade G, Moulon I . The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcome. Eur J Clin Pharmacol. 2003; 58(9):573-80. DOI: 10.1007/s00228-002-0532-8. View

Plagnol A, Rowley E, Martin P, Livesey F . Industry perceptions of barriers to commercialization of regenerative medicine products in the UK. Regen Med. 2009; 4(4):549-59. DOI: 10.2217/rme.09.21. View

Shire S . Formulation and manufacturability of biologics. Curr Opin Biotechnol. 2009; 20(6):708-14. DOI: 10.1016/j.copbio.2009.10.006. View

Paul S, Mytelka D, Dunwiddie C, Persinger C, Munos B, Lindborg S . How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010; 9(3):203-14. DOI: 10.1038/nrd3078. View

Van Wilder P . Advanced Therapy Medicinal Products and Exemptions to the Regulation 1394/2007: How Confident Can We be? An Exploratory Analysis. Front Pharmacol. 2012; 3:12. PMC: 3278850. DOI: 10.3389/fphar.2012.00012. View

Maciulaitis R, DApote L, Buchanan A, Pioppo L, Schneider C . Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive. Mol Ther. 2012; 20(3):479-82. PMC: 3293601. DOI: 10.1038/mt.2012.13. View

Tsiftsoglou A, Ruiz S, Schneider C . Development and regulation of biosimilars: current status and future challenges. BioDrugs. 2013; 27(3):203-11. DOI: 10.1007/s40259-013-0020-y. View

Abou-El-Enein M, Romhild A, Kaiser D, Beier C, Bauer G, Volk H . Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. Cytotherapy. 2013; 15(3):362-83. DOI: 10.1016/j.jcyt.2012.09.006. View

Pearce K, Hildebrandt M, Greinix H, Scheding S, Koehl U, Worel N . Regulation of advanced therapy medicinal products in Europe and the role of academia. Cytotherapy. 2013; 16(3):289-97. DOI: 10.1016/j.jcyt.2013.08.003. View

10.

Shi S . Biologics: an update and challenge of their pharmacokinetics. Curr Drug Metab. 2014; 15(3):271-90. DOI: 10.2174/138920021503140412212905. View

11.

Pariser A, Gahl W . Important role of translational science in rare disease innovation, discovery, and drug development. J Gen Intern Med. 2014; 29 Suppl 3:S804-7. PMC: 4124126. DOI: 10.1007/s11606-014-2881-2. View

12.

Bisson I, Green E, Sharpe M, Herbert C, Hyllner J, Mount N . Landscape of current and emerging cell therapy clinical trials in the UK: current status, comparison to global trends and future perspectives. Regen Med. 2015; 10(2):169-79. DOI: 10.2217/rme.14.71. View

13.

Galli M . ATMPs for Cancer Immunotherapy: A Regulatory Overview. Methods Mol Biol. 2016; 1393:1-9. DOI: 10.1007/978-1-4939-3338-9_1. View

14.

Wilde S, Veltrop-Duits L, Hoozemans-Strik M, Ras T, Blom-Veenman J, Guchelaar H . Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation. Cytotherapy. 2016; 18(6):797-805. DOI: 10.1016/j.jcyt.2016.02.010. View

15.

Hanna E, Remuzat C, Auquier P, Toumi M . Advanced therapy medicinal products: current and future perspectives. J Mark Access Health Policy. 2016; 4. PMC: 4846788. DOI: 10.3402/jmahp.v4.31036. View

16.

Codinach M, Blanco M, Ortega I, Lloret M, Reales L, Coca M . Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow-derived multipotent mesenchymal stromal cells. Cytotherapy. 2016; 18(9):1197-208. DOI: 10.1016/j.jcyt.2016.05.012. View

17.

Wilde S, Guchelaar H, Zandvliet M, Meij P . Clinical development of gene- and cell-based therapies: overview of the European landscape. Mol Ther Methods Clin Dev. 2016; 3:16073. PMC: 5130079. DOI: 10.1038/mtm.2016.73. View

18.

Kitala D, Kawecki M, Klama-Baryla A, Labus W, Glik J, Kraut M . The Isolation and Production of the Ready-to-Use Product (the Amniotic Stem Cell Culture) in Accordance with Good Manufacturing Practice Regulations. Stem Cells Dev. 2017; 26(9):694-707. DOI: 10.1089/scd.2016.0198. View

19.

Mengal P, Wubbolts M, Zika E, Ruiz A, Brigitta D, Pieniadz A . Bio-based Industries Joint Undertaking: The catalyst for sustainable bio-based economic growth in Europe. N Biotechnol. 2017; 40(Pt A):31-39. DOI: 10.1016/j.nbt.2017.06.002. View

20.

Jorgensen J, Kefalas P . Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test. J Mark Access Health Policy. 2017; 5(1):1355203. PMC: 5560408. DOI: 10.1080/20016689.2017.1355203. View